Terms: = Endocrine gland cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Staging
10 results:
1. Effects of MFG-E8 expression on the biological characteristics of ovarian cancer cells via the AKT/mtor/S6K signalling pathway.
Li N; Wang Y; Liu L; Wang P; Wu X
J Obstet Gynaecol; 2023 Dec; 43(1):2151354. PubMed ID: 36484512
[TBL] [Abstract] [Full Text] [Related]
2. Molecular profile of pancreatic neuroendocrine neoplasms (PanNENs): Opportunities for personalized therapies.
Arakelyan J; Zohrabyan D; Philip PA
Cancer; 2021 Feb; 127(3):345-353. PubMed ID: 33270905
[TBL] [Abstract] [Full Text] [Related]
3. [What is new in the pathology of pancreatic neuroendocrine tumors?].
Komminoth P; Perren A
Pathologe; 2015 May; 36(3):220-8. PubMed ID: 25941099
[TBL] [Abstract] [Full Text] [Related]
4. Role of (18) F-FDOPA PET/CT imaging in endocrinology.
Santhanam P; Taïeb D
Clin Endocrinol (Oxf); 2014 Dec; 81(6):789-98. PubMed ID: 25056984
[TBL] [Abstract] [Full Text] [Related]
5. PI3K-AKT-mtor-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms.
Briest F; Grabowski P
Theranostics; 2014; 4(4):336-65. PubMed ID: 24578720
[TBL] [Abstract] [Full Text] [Related]
6. Mammalian target of rapamycin signaling activation patterns in pancreatic neuroendocrine tumors.
Komori Y; Yada K; Ohta M; Uchida H; Iwashita Y; Fukuzawa K; Kashima K; Yokoyama S; Inomata M; Kitano S
J Hepatobiliary Pancreat Sci; 2014 Apr; 21(4):288-95. PubMed ID: 24002888
[TBL] [Abstract] [Full Text] [Related]
7. Expression of the mtor pathway regulators in human pituitary adenomas indicates the clinical course.
Jia W; Sanders AJ; Jia G; Liu X; Lu R; Jiang WG
Anticancer Res; 2013 Aug; 33(8):3123-31. PubMed ID: 23898069
[TBL] [Abstract] [Full Text] [Related]
8. Expression of PTEN and mtor in pancreatic neuroendocrine tumors.
Han X; Ji Y; Zhao J; Xu X; Lou W
Tumour Biol; 2013 Oct; 34(5):2871-9. PubMed ID: 23686804
[TBL] [Abstract] [Full Text] [Related]
9. Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches.
Oberg K
Curr Opin Oncol; 2012 Jul; 24(4):433-40. PubMed ID: 22510940
[TBL] [Abstract] [Full Text] [Related]
10. Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy.
Alexandraki KI; Kaltsas G
Endocrine; 2012 Feb; 41(1):40-52. PubMed ID: 22124940
[TBL] [Abstract] [Full Text] [Related]
